Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115555 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Hongwei Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, She…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Education of Liaoning Province, Fujian University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Tumors can evade immunity through the PD-1/PD-L1 pathway. PD-1/PD-L1 inhibitors have demonstrated therapeutic efficacy across a broad range of cancer types. However, the poor response of PD-1/PD-L1 inhibitors monotherapy limits their clinical application. PD-1/PD-L1 inhibitors and inflammatory factors exhibit synergistic anti-tumor effects. Inflammatory factors can regulate the expression of PD-L1 and affect the occurrence and development of tumors. Therefore, the combination of inflammatory factors and PD-1 inhibitors is a reasonable way to overcome the primary resistance of PD-1/PD-L1 inhibitors. However, the potential clinical risk of cytokine storm associated with this combination strategy warrants significant attention. This article reviews the interaction between inflammatory factors and the PD-1/PD-L1 pathway and discusses the possibility of combining inflammatory factors and PD-1 inhibitors to reverse this resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Institute of Structural Pharmacology & TCM Chemical Biology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
- Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: sywysdj@163.com.
- Institute of Structural Pharmacology & TCM Chemical Biology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. Electronic addr…
- Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: syzyclx@163.com.
Förderung
- National Natural Science Foundation of China
- Department of Education of Liaoning Province
- Fujian University of Traditional Chinese Medicine
Zitieren
APA
Yan, H., Wang, Y., Zhu, M., Sun, D., Li, H., & Chen, L. (2025). Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115555
Vancouver
Yan H, Wang Y, Zhu M, Sun D, Li H, Chen L. Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115555
BibTeX
@article{Yan2025,
author = {Yan, Hongwei and Wang, Yali and Zhu, Man and Sun, Dejuan and Li, Hua and Chen, Lixia},
title = {Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115555}
}
EUVIMED